Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930887 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
A Phase 2 study of Migraine and Cluster Headache, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04930887 is a Phase 2 study of Migraine and Cluster Headache that is actively recruiting participants, run by Stanford University. The registered enrollment target is 15 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04930887, a Phase 2 study of Migraine and Cluster Headache, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).
Conditions Studied
Interventions
- DRUG Saline
- DRUG Exparel (Bupivacaine Liposome)
Study Locations (1)
California
- Peter H Hwang - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930887
The ClinicalTrials.gov registry entry for NCT04930887 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04930887 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04930887 about?
NCT04930887 is a clinical study titled "Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain". Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducte...
What is the current status of trial NCT04930887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-02-01. Estimated completion is 2030-06.
What conditions does trial NCT04930887 study?
This clinical trial studies the following conditions: Migraine, Cluster Headache, Paroxysmal Hemicrania, Craniofacial Pain, Trigeminal Autonomic Cephalgia.
What interventions are being tested in trial NCT04930887?
The interventions under investigation include: Saline (DRUG), Exparel (Bupivacaine Liposome) (DRUG).
Who is sponsoring clinical trial NCT04930887?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04930887 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
-
CHOCOlate MeLatonin for AdolescenT MigrainE
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.